Meropenem
ميروبينيم هو عامل مضاد للجراثيم من فئة الكاربابينيم.
المنتجات مخصصة للاستخدام البحثي فقط، وليست للاستخدام البشري. نحن لا نبيع للمرضى.
| Pack Size | Price | Availability | Quantity | Action |
|---|---|---|---|---|
| 10mM (in 1mL DMSO) | $28.00 | In Stock | 1 | |
| 25mg | $26.00 | In Stock | 1 | |
| 50mg | $35.00 | In Stock | 1 | |
| 100mg | $49.00 | In Stock | 1 | |
| 500mg | $127.00 | In Stock | 1 |
المراجع (Citations)
2 publicationsمنشورات الباحثين الذين استخدموا هذا المنتجالوصف (Description)
Meropenem is a carbapenem antibacterial agent[1]. The MICs of meropenem was 0.03 mg/L against S. aureus and E. coli but > 256 mg/L against C. albicans[2]. It is stable to hydrolysis by most beta-lactamases produced by Gram-negative and Gram-positive bacteria, including penicillinases and cephalosporinases[1].
Meropenem, a carbapenem antibacterial agent, is stable to hydrolysis by most beta-lactamases produced by Gram-negative and Gram-positive bacteria, including penicillinases and cephalosporinases[1]. The MICs of meropenem was 0.03 mg/L against S. aureus and E. coli but > 256 mg/L against C. albicans[2].
In vitro, meropenem has the minimum inhibitory concentration (MIC) values is 128 µg/mL, but meropenem combined with vaborbactam reduced the minimum inhibitory concentration (MIC) values of meropenem by ≥ 64-fold against engineered strains and clinical isolates producing class A serine carbapenemases (e.g. KPC-2, KPC-3, SME-2, NMC-A)[3][4]. The minimum inhibitory concentrations of carvacrol and meropenem on carbapenem-resistant K. pneumoniae (CRKP) strains were detected within a range of 32-128 µg/mL using the broth microdilution method[5]. The MIC90 of meropenem (when tested with a fixed concentration of 8 µg/ml of vaborbactam) for isolates of KPC-positive Enterobacteriaceae was 1 µg/ml, and MIC values ranged from ≤0.03 to >32 µg/ml[6].
In vivo, in fully PTZ (pentylenetetrazol)-kindled mice, intravenous administration of meropenem (500 mg/kg) did not elicit any convulsions in the electroconvulsive shock test with low-intensity stimulus currents[7]. In vivo efficacy test shown that cats were administrated 10 mg/kg q12h meropenem is effected against bacteria with MIC values of 6 µg/ml, 7 µg/ml and 10 µg/ml for IV, IM and SC administration, respectively[8].
References:
[1]Zhanel GG, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations. Drugs. 2018;78(1):65-98.
[2]Yu L, et al. Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant Klebsiella pneumoniae in vitro. Front Cell Infect Microbiol. 2019 Dec 10;9:422.
[3]Hecker SJ, et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem. 2015;58(9):3682-3692.
[4]Lomovskaya O, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(11):e01443-17.
[5]KÖse EO. In vitro activity of carvacrol in combination with meropenem against carbapenem-resistant Klebsiella pneumoniae. Folia Microbiol (Praha). 2022 Feb;67(1):143-156.
[6]Hackel MA, et al. In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01904-17.
[7]Suemaru K, et al. 5-Fluorouracil exacerbates cefepime-induced convulsions in pentylenetetrazol-kindled mice. Epilepsy Res. 2019 Nov;157:106195.
[8]Albarellos GA, et al. Pharmacokinetics of meropenem after intravenous, intramuscular and subcutaneous administration to cats. J Feline Med Surg. 2016 Dec;18(12):976-980.
البروتوكول (Protocol)
| Cell experiment [1]: | |
|
Cell lines |
Human hepatocellular carcinoma cells |
|
Preparation Method |
Depending on the specific established microtiter plate hepatotoxicity assay, HepG2/C3A cells were seeded at a density of 5 × 105 cells/mL in 24-well tissue culture plates. Cells were treated with seven antibiotics at varying concentrations: Ampicillin (430 µM, 2150 µM, and 4300 µM), cefepime (210 µM, 1050 µM, and 2100 µM), cefuroxime (140 µM, 700 µM, and 1400 µM), levofloxacin (18 µM, 90 µM, and 180 µM) , linezolid (44 µM, 220 µM, and 440 µM) , meropenem (130 µM, 650 µM, and 1300 µM), rifampicin (24 µM, 120 µM, and 240 µM) , tigecycline (0.85 µM, 4.25 µM, and 8.5 µM), and vancomycin (0.0069 µM, 0.0345 µM, and 0.069 µM) for 2 × 3 days. The lowest concentrations of the various antibiotics, i.e., the mean plasma level after induction of I.V. therapy (Cmax), as well as the 5-times and 10-times concentrations of Cmax, were analyzed. Whereas antibiotic-free medium or plasma served as a negative control, acetaminophen (APAP, 15.24 mM in medium) was used as a positive control. |
|
Reaction Conditions |
130 µM, 650 µM, and 1300 µM; for 2 × 3 days. |
|
Applications |
A significant increase in lactate dehydrogenase (LDH) at Cmax was detected after incubation with ampicillin, cefepime, cefuroxime, meropenem, rifampicin, tigecycline, and vancomycin. In particular LDH values increased by more than 50% compared to the negative controls (91 U/L) after treatment with ampicillin, meropenem, and rifampicin at Cmax in medium. The testing of Cmax concentrations of antibiotics in plasma showed that all LDH levels were significantly lower than in healthy plasma after 6 days. |
| Animal experiment [2]: | |
|
Animal models |
male Sprague-Dawley rats |
|
Preparation Method |
All rats underwent laparotomy with cannulation of biliopancreatic duct. Group 1 received intraductal saline injection. Acute necrotizing pancreatitis was induced in group 2, 3, 4, and 5 by intraductal injection of 3% taurocholate. Group 1 (sham operated) and group 2 were injected with saline of 0.3 mL/kg intraperitoneally (i.p). Group 3 was injected with meropenem 60 mg/kg/d i.p, group 4 with deferoxamine 80 mg/kg/d s.c and group 5 with combination of these 2 agents at the same doses. While meropenem was started 2 hours later, all treatments were started immediately after the induction of pancreatitis. |
|
Dosage form |
60 mg/kg/d i.p |
|
Applications |
Meropenem treatment reduces secondary pancreatic infections in acute pancreatitis. |
|
References: Doß S, et al. Influence of Antibiotics on Functionality and Viability of Liver Cells In Vitro. Curr Issues Mol Biol. 2022 Oct 3;44(10):4639-4657. |
|
وثائق المنتج (Product Documents)
الخصائص الكيميائية (Chemical Properties)
استخدم المحاليل المخزونة خلال 6 أشهر عند حفظها في -80°C، أو خلال شهر واحد عند حفظها في -20°C.
لتحسين الذوبانية، سخّن الأنبوب إلى 37°C وعرّضه للموجات فوق الصوتية لمدة مناسبة.
الحاسبات (Calculators)المولارية / التخفيف / الوزن الجزيئي / تحويل الوحدات / تركيبة داخل الجسم الحي / الذوبانية
Reviews
Review for Meropenem
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%